N/A N=1 Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=145 Bipolar Ventricular Tachycardia (VT) Study
Ventricular Tachycardia
Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants
Phase 4 N=16 Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Tachycardia, Ventricular
Primary: Inhibition of Idiopathic Ventricular Tachycardia
Phase 2 N=19 Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia
Ventricular Tachycardia · Cardiomyopathy · Premature Ventricular Contractions
Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events
N/A N=26 Magnetic Stimulation to Treat VT Storm
Ventricular Tachycardia
Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants
N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
Phase 2 N=69 ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Atrial Fibrillation
Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001
Phase 4 N=53 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia
Ventricular Tachycardia
Primary: Percentage of Participants Free From VT at 1 Year Post-Treatment — 62 percentage of participants free from VT
N/A N=20 Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation
Ventricular Tachycardia
Primary: Number of Participants With Procedural Success — 8; 6 Participants
N/A N=40 Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping
Tachycardia, Ventricular
Primary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants
Phase 4 N=249 Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia
Ventricular Tachycardia
Primary: The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation. — 13.3 percentage of mortality
N/A N=14 Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia
Catecholaminergic Polymorphic Ventricular Tachycardia
Primary: Number of Patients With Ventricular Ectopy or VT During Exercise Treadmill Testing — 2; 9 Participants — p=0.008
N/A N=18 Multimodality Assessment of Ventricular Scar Arrhythmogenicity.
Ventricular Tachycardia
Primary: Electrogram Duration at Digital Twin Predicted Sites Compared to Non-predicted Sites — 77.5; 65.7 ms
Phase 4 N=1,902 Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III
Heart Disease
Primary: For the Primary Endpoint the Reduction of Ventricular Therapies (ATP and Shocks) Delivered for Treating Fast Spontaneous Arrhythmia Episodes Was Measured. — 67.1; 41.9…
Phase 4 N=246 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Ventricular Tachycardia · Premature Ventricular Contraction · Stroke
Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001
Phase 2 N=22 Pilot Randomized Trial With Flecainide in ARVC Patients
Arrhythmogenic Right Ventricular Cardiomyopathy
Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001
Phase 2 N=313 Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator
Ventricular Arrhythmia
Primary: Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24…
Phase 3 N=68 A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.
Ventricular Tachycardia
Primary: Number of Participants With Inducible Sustained Ventricular Tachycardia/ Ventricular Fibrillation (VT/VF) Utilizing Standardized Stimulation Protocol. — 4; 9 Participants
N/A N=76 Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia
Ventricular Tachycardia
Primary: Number of Subjects Without Hospitalization for Ventricular Tachycardia (VT) During 6 Months — 38 Participants
Phase 4 N=925 ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy
Tachycardia, Ventricular · Ventricular Fibrillation
Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy to Terminate Fast Ventricular Tachycardia (With Cycle Length of 240ms-320msec) — 64.9; 69.7 Percentage of FVT episodes…
Phase 4 N=67 Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study
Permanent Atrial Fibrillation
Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
N/A N=134 Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)
Bradycardia
Primary: Percentage of Intrinsic Ventricular Events — 82.7; 22.8 % of intrinsic ventricular events — p=<0.0001
N/A N=918 Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Atrioventricular Block · Heart Diseases
Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…
N/A N=11 Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia
Ventricular Tachycardia
Primary: Number of Participants Who Had Inducible Ventricular Tachycardia Under General Anesthesia. — 7; 5; 5 participants
N/A N=20 Imaging With a Radio Tracer to Guide VT Ablations
Ventricular Tachycardia · Arrhythmia
Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants
Phase 4 N=605 PreFER Managed Ventricular Pacing (MVP) For Elective Replacement
Cardiovascular Diseases
Primary: Time to Event Analysis: Number of Patients Who Experienced the First Cardiovascular Hospitalization Within 2 Years Post-implant — 43; 40 number of participants — p=0.72
N/A N=180 Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial
Ventricular Tachycardia (VT)
Primary: Freedom From Recurrent VT, Cardiovascular Rehospitalization, and All-cause Mortality — 33; 25; 28; 27 Participants
N/A N=6 Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Catecholaminergic Polymorphic Ventricular Tachycardia
Primary: Number of Ventricular Ectopic Beats Recorded During Exercise (and Recovery) — 46; 0 number of ventricular beats
Phase 4 N=526 ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy
Tachycardia, Ventricular · Ventricular Fibrillation
Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy (Burst, 8 Pulses, 88 %, 1 Sequence) to Terminate All Types of Ventricular Tachycardia. — 64.7; 68.2 Percent of VT…